What's happening in the industry

FDA clears Thermo Fisher NGS companion diagnostic for three NSCLC treatments read on...

Cancer breakthrough: personalized melanoma vaccines ‘safe and effective’ in first human clinical trials read on...

Genoptix's immuno-oncology testing now covers additional tumor types read on...

Promega intends to seek FDA approval for microsatellite instability assay to assist in strategic cancer decisions read on...

PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability read on...

Illumina announces FDA-approved next-generation sequencing cancer companion diagnostic test kit read on...

Saphetor precision medicine platform now serving Aurigen patients to enhance discovery of personalized cancer therapies read on...

‘Nanolock’ detects cancer mutation; could lead to early diagnoses, personalized therapies read on...

Researchers investigate potential new tool in diagnosing breast cancer read on...

Lifetime cancer risk predicted for BRCA mutation carriers read on...

Combo immunotherapy may herald new standard of care for kidney cancer read on...

Avant Diagnostics highlights published clinical utility data for Theralink® mTOR pathway activation data predicting Tamoxifen® and other endocrine treatment response in estrogen receptor positive (ER+) breast cancer read on...

New promise of cancer immunotherapy to treat rare lymphoma read on...

MDxHealth launches AssureMDx for bladder cancer liquid biopsy test read on...

RAS screening in colorectal cancer: results from UK NEQAS colorectal cancer external quality assurance schemes (2009–2016) read on...

PD-L2 helps predict immunotherapy responsiveness for head and neck cancer read on...

Mutation burden and PD-L1 expression influence response to nivolumab in NSCLC read on...

Adaptive Biotechnologies announces a collaboration with Janssen Biotech, Inc. to use the clonoSEQ® assay in DARZALEX® multiple myeloma trials read on...

SEngine Precision Medicine signs new licensing agreement with Fred Hutchinson Cancer Research Center read on...

University of California San Diego and Tempus partner on personalized medicine initiative read on...

Genoptix, Bionano Genomics announce strategic alliance for hematologic oncology diagnostics read on...

Celgene signs deal with BeiGene for tumor cancer treatment read on...

Quest Diagnostics completes acquisition of Med Fusion and Clear Point in Texas, forming National Precision Oncology Center of Excellence read on...

Enterome, Nestlé Health Sciences ink JV to create new diagnostics company, Microbiome Diagnostics Partners read on...

Chinese company completes acquisition of US firm providing immunotherapy for prostate cancer read on...

New inhibitor drug shows promise in relapsed leukemia read on...

First-line nivolumab in advanced lung cancer fails to improve outcomes read on...

J&J immunotherapy Darzalex ok'd for expanded combination use read on...

Clovis to apply for expanded FDA approval for Rubraca in ovarian cancer patients read on...

Three pembrolizumab myeloma trials placed on clinical hold by FDA read on...

England's chief medical officer aims to make DNA testing "available to more patients" read on...

What you might have missed

Listen to our latest webinar - Moving beyond the hype: the reality of NGS in oncology today and in the future
Better Testing Ebook: how testing can play a central role in achieving the optimal economic model
Article: A new disease level precision medicine model - starting with melanoma